Figure 6

Bupivacaine increased GSK-3β, pGSK-3βtyr216 and pGSK-3βser9 activation in ovarian cancer (SKOV-3) but not prostate cancer (PC-3) cells.
Cells were treated with 1 mM bupivacaine for 24 h followed by immunostaining. (A) Total GSK-3β, (B) pGSK-3βtyr216 and (C) pGSK-3βser9 expression in SKOV-3 cells. (D) Total GSK-3β, (E) pGSK-3βtyr216 and (F) pGSK-3βser9 expression in PC-3 cells. Data are presented by mean ± SD (n = 4). ***P < 0.001. Scale bar = 50 μm.